[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2006008005A3 - Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 2 (hzf2) - Google Patents

Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 2 (hzf2) Download PDF

Info

Publication number
WO2006008005A3
WO2006008005A3 PCT/EP2005/007449 EP2005007449W WO2006008005A3 WO 2006008005 A3 WO2006008005 A3 WO 2006008005A3 EP 2005007449 W EP2005007449 W EP 2005007449W WO 2006008005 A3 WO2006008005 A3 WO 2006008005A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
hzf2
therapeutics
diagnostics
diseases associated
Prior art date
Application number
PCT/EP2005/007449
Other languages
French (fr)
Other versions
WO2006008005A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts, Holger Summer filed Critical Bayer Healthcare Ag
Publication of WO2006008005A2 publication Critical patent/WO2006008005A2/en
Publication of WO2006008005A3 publication Critical patent/WO2006008005A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a human HZF2 which is associated with the infections, cardiovascular disorders, endocrine system and hormone disorders, metabolic diseases, hematological disorders, muscle-skeleton disorders, neurological disorders, cancer disorders, respiratory diseases, urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of infections, cardiovascular disorders, endocrine system and hormone disorders, metabolic diseases, hematological disorders, muscle-skeleton disorders, neurological disorders, cancer disorders, respiratory diseases, urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of HZF2 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/007449 2004-07-23 2005-07-09 Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 2 (hzf2) WO2006008005A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04017448 2004-07-23
EP04017448.4 2004-07-23

Publications (2)

Publication Number Publication Date
WO2006008005A2 WO2006008005A2 (en) 2006-01-26
WO2006008005A3 true WO2006008005A3 (en) 2006-03-30

Family

ID=35124488

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007449 WO2006008005A2 (en) 2004-07-23 2005-07-09 Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 2 (hzf2)

Country Status (1)

Country Link
WO (1) WO2006008005A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060860A2 (en) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
WO2002010453A2 (en) * 2000-07-31 2002-02-07 Gene Logic, Inc. Molecular toxicology modeling
US20030096272A1 (en) * 2001-07-30 2003-05-22 Incyte Genomics, Inc. Genes regulated by peroxisome proliferator-activated receptor gamma agonist

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060860A2 (en) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
WO2002010453A2 (en) * 2000-07-31 2002-02-07 Gene Logic, Inc. Molecular toxicology modeling
US20030096272A1 (en) * 2001-07-30 2003-05-22 Incyte Genomics, Inc. Genes regulated by peroxisome proliferator-activated receptor gamma agonist

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOILEAU C ET AL: "IN SEARCH OF MFS2 GENE, THE SECOND GENE IMPLICATED IN MARFAN SYNDROME", AMERICAN JOURNAL OF HUMAN GENETICS, AMERICAN SOCIETY OF HUMAN GENETICS, CHICAGO, IL, US, vol. 69, no. 4, SUPPL, October 2001 (2001-10-01), pages 617, XP009055667, ISSN: 0002-9297 *
DOWNES M ET AL: "TWO RECEPTOR INTERACTION DOMAINS IN THE COREPRESSOR, N-COR/RIP13, ARE REQUIRED FOR AN EFFICIENT INTERACTION WITH REV-ERBAALPHA AND RVR: PHYSICAL ASSOCIATION IS DEPENDENT ON THE E REGION OF THE ORPHAN RECEPTORS", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 24, no. 22, 1996, pages 4379 - 4386, XP001156849, ISSN: 0305-1048 *
DUMAS BRUNO ET AL: "A New Orphan Member of the Nuclear Hormone Receptor Superfamily Closely Related to Rev-Erb", MOLECULAR ENDOCRINOLOGY, vol. 8, no. 8, 1994, pages 996 - 1005, XP002351887, ISSN: 0888-8809 *
KOH YOUNG-SANG ET AL: "Linkage of the nuclear hormone receptor genes NR1D2, THRB, and RARB: Evidence for an ancient, large-scale duplication", GENOMICS, vol. 57, no. 2, 15 April 1999 (1999-04-15), pages 289 - 292, XP002351885, ISSN: 0888-7543 *
RANGAN V S ET AL: "PURIFICATION AND BIOCHEMICAL CHARACTERIZATION OF HEPATOCYTE NUCLEAR FACTOR 2 INVOLVED IN LIVER-SPECIFIC TRANSCRIPTION OF THE HUMAN ALPHA-1 ANTITRYPSIN GENE", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 15, 1990, pages 8874 - 8879, XP002351886, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2006008005A2 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2004099782A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor gpr39 (gpr39)
WO2005106491A3 (en) Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
WO2006008005A3 (en) Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 2 (hzf2)
WO2006010514A3 (en) Diagnostics and therapeutics for diseases associated with dual specificity mitogen-activated protein kinase kinase 5 (map2k5)
WO2004081563A3 (en) Diagnostics and therapeutics for diseases associated with phosphodiesterase 1a (pde1a)
WO2004099783A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4)
WO2005118840A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 10 (klk10)
WO2005074969A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a1 (nr4a1)
WO2005059546A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
WO2005095984A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled alpha 2a-adrenoceptor (adra2a)
WO2005083105A3 (en) Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 beta (gsk3b)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2005040829A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 17 (gpr17)
WO2004099781A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor rdc1 (rdc1)
WO2005113786A3 (en) Diagnostics and therapeutics for diseases associated with chymase (cma1)
WO2005114210A8 (en) Diagnostics and therapeutics for diseases associated with g protein-dependent receptor kinase 3 (grk3)
WO2004104596A3 (en) Diagnostics and therapeutics for diseases associated with igs70 (igs70)
WO2005100997A3 (en) Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3)
WO2006008008A3 (en) Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 4, alpha (hnf4a)
WO2004106934A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 7 (5-ht7)
WO2005085865A3 (en) Diagnostics and therapeutics for diseases associated with thyroid hormone receptor beta (thrb)
WO2005040824A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24)
WO2005026719A3 (en) Diagnostics and therapeutics for diseases associated with transporter slc22a3 (slc22a3)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase